CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Local or Whole Body Hyperthermia

This policy governs coverage and medical necessity determinations for local (superficial and deep) and whole-body hyperthermia used as adjunctive cancer therapy for members of Blue Cross Blue Shield - Rhode Island, affecting Medicare Advantage and Commercial products.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyLocal or Whole Body Hyperthermia

Policy CodePolicy N/A

Change TypeNo material clinical or coverage changes

Effective DateAug 1, 2025

Next Review DateJun 5, 2026

Key ActionObtain prior authorization using the online authorization tool for Medicare Advantage; submit documentation demonstrating criteria are met.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Medically necessaryMedicare Advantage when authorization tool criteria met

May be coveredCommercial when used with radiation

Not coveredWhole-body hyperthermia

RequiredPrior authorization

Coverage determinations and medical necessity

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage determinations

Coverage determinations as stated in the policy:

Medicare Advantage - Local hyperthermia: Local hyperthermia therapy is considered medically necessary when the medical criteria in the online authorization tool is met.authorization tool criteria

Prior authorization required; local hyperthermia is not covered for Medicare Advantage when authorization criteria are not met.

Commercial - Local hyperthermia with radiation: Local hyperthermia may be considered medically necessary when used in connection with radiation therapy for treatment of primary or metastatic cutaneous or subcutaneous superficial malignancies.used with radiation for superficial cutaneous/subcutaneous tumors

Prior authorization recommended; may be considered not medically necessary when the medical criteria are not met.

Local hyperthermia not with chemotherapy: Local hyperthermia is considered not medically necessary when used alone or in combination with chemotherapy due to insufficient evidence to determine effects on health outcomes.not applicable

Applies to Commercial products and clinical scenarios where only chemotherapy or hyperthermia alone are used.

Whole-body hyperthermia therapy is not covered for Medicare Advantage Plans and is not medically necessary for Commercial products because evidence is inadequate to permit scientific conclusions regarding its use as an adjunct to radiation or chemotherapy.whole-body modality

Whole-body hyperthermia requires general anesthesia/deep sedation and prolonged monitoring; no specific CPT code (report with unlisted code if attempted).

For Medicare Advantage products, local hyperthermia therapy is considered medically necessary when the medical criteria in the online authorization tool are met; prior authorization is required and services that do not meet the authorization tool criteria are not covered. For Commercial products, local hyperthermia may be considered medically necessary when used in connection with radiation therapy for primary or metastatic cutaneous or subcutaneous superficial malignancies, but it may be considered not medically necessary when the medical criteria are not satisfied. Across products, local hyperthermia is not considered medically necessary when used alone or in combination with chemotherapy due to insufficient evidence.

Whole-body hyperthermia is not covered for Medicare Advantage Plans and is not medically necessary for Commercial products because the evidence is insufficient to determine its effects on health outcomes.

Local hyperthermia used alone or with chemotherapy is explicitly stated as not medically necessary because available evidence is inadequate to demonstrate benefit when used without radiation. When local hyperthermia is intended as an adjunct, the policy supports its use only in combination with radiation therapy for superficial cutaneous or subcutaneous tumors where authorization criteria are met.

The policy considers whole-body hyperthermia—a systemic procedure that raises core body temperature and requires general anesthesia or deep sedation—to be not medically necessary (and not covered under Medicare Advantage). The document cites inadequate data regarding whole-body hyperthermia as an adjunct to radiation or chemotherapy, and therefore it is not supported for coverage.

If whole-body hyperthermia is attempted, note there is no specific CPT code for that modality in the coding section; reporting would require an unlisted code, but coverage remains not provided.

Prior authorization, documentation, and denial risks

Prior Authorization

Prior Authorization Required

Prior authorization is required for Medicare Advantage Plans. Providers should use the payer's online authorization tool and ensure the medical criteria there are met for local hyperthermia.

Medicare Advantage: prior authorization required via online authorization tool
Commercial: prior authorization recommended

Step Therapy

Therapy Sequencing and Coverage Limits

Local hyperthermia is not medically necessary when used alone or in connection with chemotherapy. Local hyperthermia should be sequenced with radiation therapy per coverage guidance; whole‑body hyperthermia is not covered for Medicare Advantage and is not medically necessary for Commercial products.

Local hyperthermia NOT medically necessary alone or with chemotherapy; use only per coverage (with radiation)
Whole‑body hyperthermia: not covered for Medicare Advantage; not medically necessary for Commercial

Documentation Required

Authorization and Documentation

Providers must submit authorization requests through the online authorization tool and include documentation that demonstrates the member meets the medical criteria in the tool for local hyperthermia. Include relevant clinical history, indication, prior treatments, and treatment plan (including radiation sequencing when applicable).

Use online authorization tool for Medicare Advantage requests
Attach clinical documentation supporting that online-tool criteria are met (indication, prior therapies, treatment plan)
Report appropriate CPT codes for local hyperthermia when criteria are met (see coding guidance)

Denial Risk

Denial Risk: Unmet Authorization Criteria

Denial risk exists when authorization criteria in the online tool are not met. For Medicare Advantage, local hyperthermia will be considered not covered if the online authorization tool criteria are not satisfied. For Commercial products, local hyperthermia may be considered not medically necessary when the medical criteria are not met.

Medicare Advantage: denial if online authorization criteria not met
Commercial: may be denied as not medically necessary if criteria not met

Clinical background

Hyperthermia is a cancer therapy that exposes tissue to elevated temperatures (documented up to 113°F) to damage and kill cancer cells. It can be delivered as local or whole-body treatment modalities.

Local hyperthermia elevates the temperature of superficial or subcutaneous tumors while sparing surrounding normal tissue, using external or interstitial techniques. Local treatments may be described as superficial (≤4 cm) or deep (>4 cm), and may be medically necessary when used with radiation for primary or metastatic cutaneous or subcutaneous superficial tumors.

Whole-body hyperthermia involves raising the patient’s core temperature (the policy describes increases to about 108°F) under general anesthesia or deep sedation, maintaining the elevated temperature for several hours with intensive monitoring and a prolonged recovery and observation period; this modality is considered not medically necessary due to inadequate evidence.

Key definitions

Local hyperthermia definition

DefinitionLocal hyperthermia elevates the temperature of superficial or subcutaneous tumors using external or interstitial modalities to spare surrounding normal tissue.

Superficial modality thresholdHeating to a depth of 4 cm or less (external superficial).

Deep modality thresholdHeating to depths greater than 4 cm (deep external) or via interstitial probes for deeper lesions.

ModalitiesExternal (superficial and deep) and interstitial (probe-based) delivery methods.

Clinical use noteMay be medically necessary when used in combination with radiation therapy for primary or metastatic cutaneous or subcutaneous superficial tumors; not medically necessary when used alone or with chemotherapy.

Whole-body hyperthermia definition

DefinitionWhole-body hyperthermia (systemic thermotherapy) raises the patient’s core body temperature under general anesthesia or deep sedation.

Core temperature targetIn the policy example, body temperature is increased to 108°F.

Treatment duration and monitoringElevated temperature maintained for ~4 hours, followed by ~1 hour cooling off and continuous observation for a minimum of 12 hours with close monitoring of essential body functions.

Delivery methodAchieved by packing the patient in heated (hot water) blankets; requires general anesthesia or deep sedation.

Coverage stanceWhole-body hyperthermia therapy is considered not medically necessary (not covered).

77600	Hyperthermia, externally generated; superficial (ie, heating to a depth of 4 cm or less).
77605	Hyperthermia, externally generated; deep (ie, heating to depths greater than 4 cm).
77610	Hyperthermia generated by interstitial probe(s); 5 or fewer interstitial applicators.
77615	Hyperthermia generated by interstitial probe(s); more than 5 interstitial applicators.
77620	Hyperthermia generated by intracavitary probe(s).

OpenPayer

Local or Whole Body Hyperthermia

Coverage determinations and medical necessity

Billing and coding

Prior authorization, documentation, and denial risks

Clinical background

Key definitions